Overview

Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Osimertinib (TAGRISSO) (ROSY-T)

Status:
Not yet recruiting

Trial end date:
2026-03-13

Target enrollment:

Participant gender:

Summary

The rationale of the ROSY-T study is to continue to provide study treatment for patients who have participated in a parent study with osimertinib and who are continuing to derive clinical benefit from treatment at the end of such studies, as judged by the Investigator.

Phase:

Phase 3

Details

Lead Sponsor:

AstraZeneca

Collaborator:

Parexel

Treatments:

Osimertinib